117 related articles for article (PubMed ID: 20079210)
1. [The effects and safety of bortezomib combined with dexamethasone in the treatment of primary systemic amyloidosis].
Li J; Zhao Y; Zeng LJ; Su C; Wang HH
Zhonghua Nei Ke Za Zhi; 2009 Sep; 48(9):741-4. PubMed ID: 20079210
[TBL] [Abstract][Full Text] [Related]
2. Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone.
Kastritis E; Anagnostopoulos A; Roussou M; Toumanidis S; Pamboukas C; Migkou M; Tassidou A; Xilouri I; Delibasi S; Psimenou E; Mellou S; Terpos E; Nanas J; Dimopoulos MA
Haematologica; 2007 Oct; 92(10):1351-8. PubMed ID: 18024372
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of the combination of bortezomib and dexamethasone in systemic AL amyloidosis.
Lamm W; Willenbacher W; Lang A; Zojer N; Müldür E; Ludwig H; Schauer-Stalzer B; Zielinski CC; Drach J
Ann Hematol; 2011 Feb; 90(2):201-6. PubMed ID: 20821326
[TBL] [Abstract][Full Text] [Related]
4. Treatment of IgM-associated AL amyloidosis with the combination of rituximab, bortezomib, and dexamethasone.
Palladini G; Foli A; Russo P; Milani P; Obici L; Lavatelli F; Merlini G
Clin Lymphoma Myeloma Leuk; 2011 Feb; 11(1):143-5. PubMed ID: 21454217
[TBL] [Abstract][Full Text] [Related]
5. Translocation t(11;14) is associated with adverse outcome in patients with newly diagnosed AL amyloidosis when treated with bortezomib-based regimens.
Bochtler T; Hegenbart U; Kunz C; Granzow M; Benner A; Seckinger A; Kimmich C; Goldschmidt H; Ho AD; Hose D; Jauch A; Schönland SO
J Clin Oncol; 2015 Apr; 33(12):1371-8. PubMed ID: 25779559
[TBL] [Abstract][Full Text] [Related]
6. Lenalidomide and dexamethasone for systemic AL amyloidosis following prior treatment with thalidomide or bortezomib regimens.
Mahmood S; Venner CP; Sachchithanantham S; Lane T; Rannigan L; Foard D; Pinney JH; Gibbs SD; Whelan CJ; Lachmann HJ; Gillmore JD; Hawkins PN; Wechalekar AD
Br J Haematol; 2014 Sep; 166(6):842-8. PubMed ID: 24930361
[TBL] [Abstract][Full Text] [Related]
7. Quick response to bortezomib plus dexamethasone in a patient with AL amyloidosis in first relapse.
Moscetti A; Saltarelli F; Bianchi MP; Monarca B; De Biase L; Porrini R; Antolino G; La Verde G
Amyloid; 2011 Jun; 18 Suppl 1():152-4. PubMed ID: 21838469
[No Abstract] [Full Text] [Related]
8. Bortezomib in combination with dexamethasone and subsequent thalidomide for newly-diagnosed multiple myeloma: a Chinese experience.
Zheng W; Wei G; Ye X; He J; Li L; Wu W; Shi J; Zhang J; Huang W; Xie W; Luo Y; Xue X; Lin M; Huang H; Cai Z
Leuk Res; 2009 Dec; 33(12):1615-8. PubMed ID: 19773080
[TBL] [Abstract][Full Text] [Related]
9. Long-term outcomes of primary systemic light chain (AL) amyloidosis in patients treated upfront with bortezomib or lenalidomide and the importance of risk adapted strategies.
Kastritis E; Roussou M; Gavriatopoulou M; Migkou M; Kalapanida D; Pamboucas C; Kaldara E; Ntalianis A; Psimenou E; Toumanidis ST; Tasidou A; Terpos E; Dimopoulos MA
Am J Hematol; 2015 Apr; 90(4):E60-5. PubMed ID: 25580702
[TBL] [Abstract][Full Text] [Related]
10. [Outcomes of AL-amyloidosis treatment with bortezomib, dexamethasone and cyclophosphamide or doxorubicin-containing regimens].
Adam Z; Stork M; Pour L; Krejčí M; Zahradová L; Sandecká V; Hájek R; Cermáková Z; Pospíšilová Y; Navrátil M; Král Z; Mayer J
Vnitr Lek; 2012 Dec; 58(12):896-903. PubMed ID: 23427947
[TBL] [Abstract][Full Text] [Related]
11. Successful treatment of renal light chain (AL) amyloidosis with bortezomib and dexamethasone (VD).
Huang B; Li J; Xu X; Zheng D; Zhou Z; Liu J
Pathol Biol (Paris); 2015 Feb; 63(1):17-20. PubMed ID: 25455933
[TBL] [Abstract][Full Text] [Related]
12. Extended follow-up of a phase 2 trial of bortezomib alone and in combination with dexamethasone for the frontline treatment of multiple myeloma.
Jagannath S; Durie BG; Wolf JL; Camacho ES; Irwin D; Lutzky J; McKinley M; Potts P; Gabayan AE; Mazumder A; Crowley J; Vescio R
Br J Haematol; 2009 Sep; 146(6):619-26. PubMed ID: 19622094
[TBL] [Abstract][Full Text] [Related]
13. Salvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib, and thalidomide.
Palladini G; Russo P; Foli A; Milani P; Lavatelli F; Obici L; Nuvolone M; Brugnatelli S; Invernizzi R; Merlini G
Ann Hematol; 2012 Jan; 91(1):89-92. PubMed ID: 21533608
[TBL] [Abstract][Full Text] [Related]
14. [Curative effect observation of patients with primary systemic amyloidosis treated by the combination of bortezomib with dexamethasone and cyclophosphamide].
Lu J; Wang H; Huang XJ
Zhonghua Xue Ye Xue Za Zhi; 2013 Apr; 34(4):345-8. PubMed ID: 23668210
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of triplet regimens in newly diagnosed light chain amyloidosis.
Chari A; Barley K; Jagannath S; Osman K
Clin Lymphoma Myeloma Leuk; 2013 Feb; 13(1):55-61. PubMed ID: 23098888
[TBL] [Abstract][Full Text] [Related]
16. Bortezomib, melphalan, and prednisolone combination chemotherapy for newly diagnosed light chain (AL) amyloidosis.
Lee JY; Lim SH; Kim SJ; Lee GY; Lee JE; Choi JO; Kim JS; Kim HJ; Lee SY; Min JH; Jeon ES; Kim K
Amyloid; 2014 Dec; 21(4):261-6. PubMed ID: 25248716
[TBL] [Abstract][Full Text] [Related]
17. [Efficacy of bortezomib combined dexamethasone in 24 patients with multiple myeloma].
Li J; Zhao Y; Luo SK; Huang BH; Ding Y; Tong XZ; Wang HH; Zheng D; Su C; Peng AH
Ai Zheng; 2008 Apr; 27(4):429-34. PubMed ID: 18423132
[TBL] [Abstract][Full Text] [Related]
18. [Treatment of AL-amyloidosis--results from one clinic and review of published experience with new agents (bortezomib, thalidomide and lenalidomide) in AL-amyloidosis].
Adam Z; Pour L; Krejcí M; Zahradová L; Krivanová A; Mardová J; Kovárová L; Stepánková S; Moulis M; Kren L; Veselý K; Svobodová I; Germáková Z; Nedbálková M; Mayer J; Hájek R
Vnitr Lek; 2010 Mar; 56(3):190-209. PubMed ID: 20394205
[TBL] [Abstract][Full Text] [Related]
19. United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy.
Kane RC; Farrell AT; Sridhara R; Pazdur R
Clin Cancer Res; 2006 May; 12(10):2955-60. PubMed ID: 16707588
[TBL] [Abstract][Full Text] [Related]
20. Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial.
Kim HJ; Yoon SS; Lee DS; Sohn SK; Eom HS; Lee JL; Chung JS; Kim K; Suh C; Won JH; Kim JS; Park JS; Kang HJ; Seong CM; Kim CS; Lee SJ; Lee JH
Ann Hematol; 2012 Feb; 91(2):249-56. PubMed ID: 21789621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
